CA2940928C - Transmembrane cd154 proteins with oligomerization domain and medical uses thereof - Google Patents

Transmembrane cd154 proteins with oligomerization domain and medical uses thereof Download PDF

Info

Publication number
CA2940928C
CA2940928C CA2940928A CA2940928A CA2940928C CA 2940928 C CA2940928 C CA 2940928C CA 2940928 A CA2940928 A CA 2940928A CA 2940928 A CA2940928 A CA 2940928A CA 2940928 C CA2940928 C CA 2940928C
Authority
CA
Canada
Prior art keywords
seq
cells
tmz
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2940928A
Other languages
English (en)
French (fr)
Other versions
CA2940928A1 (en
Inventor
Angelica Loskog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lokon Pharma AB
Original Assignee
Lokon Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50542800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2940928(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lokon Pharma AB filed Critical Lokon Pharma AB
Publication of CA2940928A1 publication Critical patent/CA2940928A1/en
Application granted granted Critical
Publication of CA2940928C publication Critical patent/CA2940928C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
CA2940928A 2014-04-07 2015-04-07 Transmembrane cd154 proteins with oligomerization domain and medical uses thereof Active CA2940928C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163704 2014-04-07
EP14163704.1 2014-04-07
PCT/EP2015/057489 WO2015155174A1 (en) 2014-04-07 2015-04-07 New medical agents and uses thereof

Publications (2)

Publication Number Publication Date
CA2940928A1 CA2940928A1 (en) 2015-10-15
CA2940928C true CA2940928C (en) 2024-01-09

Family

ID=50542800

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2940928A Active CA2940928C (en) 2014-04-07 2015-04-07 Transmembrane cd154 proteins with oligomerization domain and medical uses thereof

Country Status (13)

Country Link
US (1) US10973875B2 (es)
EP (1) EP3129398B1 (es)
JP (1) JP6524208B2 (es)
CN (1) CN106459991B (es)
AU (1) AU2015243562B2 (es)
CA (1) CA2940928C (es)
DK (1) DK3129398T3 (es)
ES (1) ES2744479T3 (es)
NZ (1) NZ724775A (es)
PL (1) PL3129398T3 (es)
PT (1) PT3129398T (es)
RU (1) RU2739073C2 (es)
WO (1) WO2015155174A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816825D0 (en) * 2018-10-16 2018-11-28 Phoremost Ltd Target for anti-cancer therapy
EP3927833A4 (en) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
US20220175781A1 (en) * 2019-03-08 2022-06-09 Obsidian Therapeutics, Inc. Cd40l compositions and methods for tunable regulation
GB201910605D0 (en) * 2019-07-24 2019-09-04 Immetacyte Ltd Tumour infltracting lymphocyte therapy amd uses thereo
CN120535659B (zh) * 2025-07-29 2025-10-17 苏州大学 一种骨靶向的三聚体蛋白及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT672141E (pt) * 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
ES2309224T3 (es) * 2001-12-21 2008-12-16 Immunex Corporation Polipeptidos recombinantes.
PL1699480T3 (pl) * 2003-12-30 2011-11-30 Mologen Ag Allogeniczny przeciwnowotworowy czynnik terapeutyczny
EP2441846A3 (en) * 2006-01-09 2012-07-25 The Regents Of the University of California Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy

Also Published As

Publication number Publication date
WO2015155174A1 (en) 2015-10-15
ES2744479T3 (es) 2020-02-25
JP6524208B2 (ja) 2019-06-05
CN106459991B (zh) 2021-03-05
CN106459991A (zh) 2017-02-22
JP2017512504A (ja) 2017-05-25
NZ724775A (en) 2022-07-29
CA2940928A1 (en) 2015-10-15
RU2739073C2 (ru) 2020-12-21
EP3129398B1 (en) 2019-06-26
EP3129398A1 (en) 2017-02-15
US10973875B2 (en) 2021-04-13
US20170189480A1 (en) 2017-07-06
RU2016142370A3 (es) 2018-12-14
AU2015243562A1 (en) 2016-10-20
AU2015243562B2 (en) 2019-02-28
PT3129398T (pt) 2019-09-06
DK3129398T3 (da) 2019-08-26
PL3129398T3 (pl) 2019-12-31
RU2016142370A (ru) 2018-05-07

Similar Documents

Publication Publication Date Title
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
JP7258364B2 (ja) がんおよび関連悪性腫瘍の治療のためのγδＴ細胞を活性化、修飾、および増殖させる方法
ES2963718T3 (es) Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
AU2026201764A1 (en) Oncolytic virus therapy
CA2940928C (en) Transmembrane cd154 proteins with oligomerization domain and medical uses thereof
JP7317158B2 (ja) Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９～３７７位エピトープに特異的な完全ヒトＴ細胞受容体
JP2021008481A (ja) 悪性腫瘍の治療に対する方法
CN111094553A (zh) 用于癌症治疗的改良同种异体树突状细胞
JP5485139B2 (ja) 遺伝子導入細胞の製造方法
CN109134660A (zh) 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途
US20250319144A1 (en) Recombinant Armed Oncolytic Virus Composition and Use Thereof in TIL Adoptive Therapy
JP2024533109A (ja) キメラ抗原受容体（ｃａｒ）ｔ細胞療法プラットフォーム
TWI723354B (zh) 用於癌症治療之工程化幹細胞
Dowell Studies of human T cell costimulation: potential for the immunotherapy of cancer
WO2026007901A1 (zh) 共表达细胞因子的FLT3-CAR-γδT细胞及其应用
WO2024109906A1 (zh) 一种融合多肽及其用途
HK40037307A (en) A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
HK40037307B (en) A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
EA048022B1 (ru) Вирусные векторы и их применение в адоптивной клеточной терапии
JP2010099022A (ja) リンパ球の製造方法
HK40007925A (en) Adenovirus and immunomodulator combination therapy
HK1247626B (en) A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
JP2010094123A (ja) リンパ球の製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200226

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250207

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260209